Cencora (COR) continues to display strong momentum with growth that positions it as a significant player in the long-term. The consensus recommendation remains at a "Moderate Buy" among brokerages. The Bio-tech company made strategic healthcare acquisitions and was able to raise $1.8B in senior notes offerings. Though its
earnings growth rate appears to underperform, its $4.6B
acquisition of Retina Consultants is set to bolster EPS growth. Despite some uneven fiscal results and lower price targets, its robust financial performance and strategic acquisitions demonstrate a strong potential for growth. The investment from various institutions and lowering of stakes by others like Walgreens Boots Alliance is noteworthy. Some concerns about Cencora's earnings and share price persist, yet it continues to display strength, even amid EPS challenges. Its shares recently hit a fresh high, and several holdings were boosted significantly. The
Q4 2024 earnings witnessed a surge of 14.7% to $79.1B, and the dividend to shareholders has been increased. Despite some limited concerns, the company maintains a strong position in the biotech market, promising an optimistic outlook for current holders of Cencora in their portfolio.
Cencora COR News Analytics from Wed, 22 May 2024 07:00:00 GMT to Fri, 20 Dec 2024 15:09:36 GMT -
Rating 7
- Innovation 4
- Information 8
- Rumor 2
